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Background: The X-linked ribosomal protein S4 (RPS4X), which is involved in cellular translation and proliferation,
has previously been identified as a partner of the overexpressed multifunctional protein YB-1 in several breast
cancer cells. Depletion of RPS4X results in consistent resistance to cisplatin in such cell lines.
Methods: As platinum-based chemotherapy is a standard first line therapy used to treat patients with ovarian
cancer, we evaluated the prognostic value of RPS4X and YB-1 at the protein level in specimen from 192 high-grade
serous epithelial ovarian cancer patients.
Results: Immunohistochemistry studies indicated that high expression of RPS4X was associated with a lower risk of
death and later disease progression (HR = 0.713, P = 0.001 and HR = 0.761, P = 0.001, respectively) as compared to
low expression of RPS4X. In contrast, YB-1 was not significantly associated with either recurrence or survival time in
this cohort. Finally, the depletion of RPS4X with different siRNAs in two different ovarian cancer cell lines reduced
their proliferative growth rate but more importantly increased their resistance to cisplatin.
Conclusion: Altogether, these results suggest that the levels of RPS4X could be a good indicator for resistance to
platinum-based therapy and a prognostic marker for ovarian cancer. Our study also showed that RPS4X is an
independent prognostic factor in patients with serous epithelial ovarian cancer.
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Epithelial ovarian cancer (EOC) is a disease responsible
for more cancer deaths among women in the Western
world than all other gynecologic malignancies. Because
of its asymptomatic nature, ovarian cancer is character-
ized at presentation with advanced disease having spread
primarily via an intraperitoneal route. An initial surgical
approach is essential for proper staging of the disease
process and for aggressive cytoreduction, which in turn
improves the response to chemotherapy and survival [1].
Chemotherapy has had an increasingly important role in* Correspondence: michel.lebel@crhdq.ulaval.ca
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reproduction in any medium, provided the orthe effective treatment of ovarian cancer. The refer-
ence standard for postsurgical ovarian cancer first-line
chemotherapy has been the use of a platinum–taxane
combination [2]. Although the standard platinum-
taxane regimen results in a response rate of 80% in ad-
vanced ovarian cancer patients, most of these patients
relapse after a median period of 18 months, due to the
emergence of tumor resistance to these conventional
drugs [3-5]. Thus, there is an immediate need for the
identification of pharmacogenomic markers to identify
patients unlikely to respond, those that will relapse rap-
idly, or patients at risk for severe toxicity.
In recent years, several studies have reported the involve-
ment of YB-1 in patient survival and cisplatin resistance in
ovarian cancers [6,7]. The YB-1 protein is a multifunctional
protein that affects the transcription, splicing, and trans-
lation of specific mRNAs [8-11]. Increased expression ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Description of the high-grade serous ovarian
carcinomas (HGSOC) tissue array










<1 cm 29 (15.1)
1-2 cm 16 (8.3)
2 cm 63 (32.8)
Variable N = 192
mean (SD)
Age, years 62 (11)
Disease free survival, month 22 (26)
Overall survival, month 35 (29)
Stage is divided in 4 categories according to FIGO classification. Residual
disease at surgery time (Res. Disease) was evaluated by a gyneco-oncologist
(in cm). negative = no residual disease. milliary = very small, discrete, multiple
areas of tumor tissue, and is grouped by convention with the <1 cm group.
Abbreviations: SD standard deviation.
Tsofack et al. BMC Cancer 2013, 13:303 Page 2 of 12
http://www.biomedcentral.com/1471-2407/13/303YB-1 is associated with a poor prognosis in ovarian can-
cer [7]. YB-1 binds preferentially to cisplatin-modified
DNA [12] and interacts with several DNA repair proteins
[13,14]. Although YB-1 affects several biological processes,
it is still unknown which ones are important for cisplatin
resistance. In a recent study of breast cancer cell lines, we
identified the proteins that interact directly to YB-1 and
impact on cisplatin response upon depletion [15]. Inter-
estingly, we found that the small ribosomal protein 4X
(RPS4X) increases cisplatin resistance upon depletion with
specific small interference RNAs. As platinum-based com-
pounds are used in the treatment of ovarian cancers, we
sought to correlate the levels of RPS4X in clinical samples
with patient survival and disease progression.
In this work, we determined by immunohistochemistry
the levels of both RPS4X and YB-1 in ovarian cancer sam-
ples from patients who were treated with a platinum-based
chemotherapeutic regimen after their surgery. RPS4X not
only correlated with stage, but low levels of RPS4X also
correlated with poor survival and disease progression.
These results indicate that RPS4X could be a predictive
and prognostic marker in ovarian cancer.
Methods
Ethics statement
Ethics approval for specimen collection and the study
were obtained by the local institutional ethics board
(Comité d’éthique de la recherche du Centre hospitalier
de l’Université de Montréal).
Patients and tissue specimens
Tumor samples were collected and banked following
appropriate consent from patients undergoing surgery
within the Division of Gynecologic Oncology at the Centre
hospitalier de l’Université de Montréal from 1993 to 2010.
An independent dedicated GYN-pathologist scored the
tumor grade and subtype and a gynecologic oncologist
scored the stage and the tumor residual disease according
to criteria from the International Federation of Gynecolo-
gists and Obstetricians [16]. Clinical data on progression-
free interval were defined according to RECIST 1.1 [17].
Overall survival was defined as the time from surgery to
death from ovarian cancer. Patients known to be still alive
at time of analysis were censored at time of their last
follow-up. Patient disease free survival (DFS) was calcu-
lated from the time of surgery until the first progression.
Eligibility criteria for inclusion in the study were as follows:
primary surgery, complete information on post-operative
chemotherapeutic treatment, high grade serous histopath-
ology subtype, and completed tumor banking informed
consent. Patients who died from another disease were cen-
sored at time of last follow-up. A gynecologic oncologist
reviewed the clinical data for all patients. For the disease-
free progression study, only patients with clinical follow-upof at least 18 months or until disease recurrence were in-
cluded. The characteristics of the tumors and patient out-
come for the sample sets are summarized in Table 1.
Tissue microarray (TMA)
Areas of tumor were selected based on review of a
hematoxylin-eosin-stained slide. All samples were fixed
with formalin and embedded in paraffin following a stand-
ard procedure. Formalin fixed paraffin embedded tumor
blocks were then biopsied using a 0.6 mm diameter tissue
arrayer and resultant cores were arrayed into a grid in a re-
cipient paraffin block. It has previously been demonstrated
using several different antibodies that the quality of the
core samples on this TMA was suitable for immunohisto-
chemistry and statistical analyses confirmed that the age of
the paraffin blocks was not a confounder in these studies
[18]. The tissue array was composed of 260 ovarian cancer
samples from patients that never received chemotherapy
before their surgery and 11 samples of areas from normal
fallopian tubes of cancer patients. After review of the clin-
ical data 68 patients were excluded from the final analysis,
as they did not meet the study inclusion criteria. For the
RPS4X immunostaining study, two core samples on the
TMA were damaged and thus excluded (thus N = 190).
For the YB-1 immunostaining study, six core samples were
excluded for similar reason (thus N = 186). The completed
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and received another pathology review to confirm tumor
content [18].
Immunohistochemistry
The TMA of formalin fixed paraffin embedded tumors
was sectioned at 4 μm and slides were stained using the
BenchMark XT automated stainer (Ventana Medical
System Inc.). The optimal concentration for each primary
antibody was determined by serial dilutions. The rabbit
polyclonal antibody against human RPS4X (14799-1-AP)
was purchased from ProteinTech Group, Inc. (Chicago IL).
A polyclonal antibody against the N-terminus portion
of YB-1 (ab12148) was purchased from Abcam, Inc.
(Cambridge, MA) [19,20]. The rabbit monoclonal anti-
body against Ki67 (RM-9106) was purchased from Lab
Vision (Fremont, CA). Nuclei were counterstained with
hematoxylin. Antigen retrieval was carried out with
Cell Conditioning 1 (Ventana Medical System Inc.; #950–
124) for 30 min (YB-1 and RPS4X) or 60 min (Ki67). Pre-
diluted antibody was automatically dispensed, and the
slides were incubated at 37°C for 60 min (YB-1 and
RPS4X) or 44 min (Ki67). Reactions were carried out
using the UltraView DAB detection kit (Ventana Medical
System Inc.; #760–091). Slides were counterstained with
hematoxylin (Ventana Medical System Inc.; #760–2021).
All sections were scanned with a 20x 0.75NA objective
with a resolution of 0.3225 μm. Substitution of the primary
antibody with phosphate buffered saline served as a nega-
tive control.
Staining quantification
Tumor sections were scanned, digitally conserved, and
manually visualized. For RPS4X and YB-1, a score was
given to each core according to the staining intensity
of the cytoplasm in the epithelial cells from 1 (weak)
to 5 (strong). For both markers, no cores presented
negative staining. For Ki67, cores were scored for the
percentage (rounded to the nearest 5%) of total stain-
ing. Each array was independently analyzed in a blind
study by two independent observers. We use the inter-
rating correlation (Cronbach’s Alpha) to evaluate the
overall correlation between the observers as described
previously [18]. Inter-rating correlation was >75% for all
three proteins. The average score from the two inde-
pendent observers, for each respective core, was used
for analysis.
YB-1 and RPS4X knock down
The human OVCAR-3 and SK-OV-3 serous ovarian cancer
cell lines were obtained from the American Type Culture
Collection (ATCC). The OVCAR-3 cells were main-
tained in RPMI media supplemented 15% Fetal Bovine
Serum (FBS) and 1% Penicillin-Streptomycin (Invitrogen,Carlsbad, CA) at 37°C in atmosphere of 5% CO2. The SK-
OV-3 cells were maintained in DMEM supplemented
with 10% FBS and 1% Penicillin-Streptomycin. To de-
plete RPS4X or YB-1 proteins in cells, small interfer-
ence RNA (siRNA) molecules were transfected with
the Lipofectamine 2000 as described by the manufac-
turer (Invitrogen, Carlsbad, CA). The knock down effi-
ciency was confirmed by western blot analyses with
antibodies against YB-1, RPS4X, and β-actin as control.
Horseradish peroxidase-conjugated secondary antibodies
(anti-rabbit IgG: NAV934V and anti-mouse IgG: NA931V)
were purchased from GE Healthcare Limited (Piscataway,
NJ). The siRNA sequences against YB-1 are 5′-AAGAA
GAAAUAUGAAAUUCCA-3′ for the siRNA-A molecule
and 5′-CUGCAAGCACCUGUUAAUAAA-3′ for siRNA-
B. The siRNA sequences against RPS4X are 5′-CAGA
UCUUUGUACGUAAUUAA-3′ for the siRPS4X-A mol-
ecule and 5′-CGGGAGAGAAUUUCCGUCUGA-3′ for
siRPS4X-D. A scrambled control siRNA was purchased
from Invitrogen (Carlsbad, CA).
To obtain the growth curves of transfected cells, 10,000
OVCAR-3 or 50,000 SK-OV-3 transfected cells were plated
in 60 mm dishes and counted with a hemacytometer by
the trypan blue exclusion technique every other day. Ex-
periments were performed in triplicate.
Western blots
All transfected and untransfected cells were lysed in
RIPA buffer [50 mM Tris–HCl (pH 7.5), 150 mM NaCl,
1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate] for
SDS-PAGE analyses. Proteins from SDS-PAGE were
transferred onto Amersham Hybond-P membranes (GE
Healthcare Limited, Piscataway, NJ). Membranes were
blocked one hour at room temperature in PBS containing
5% milk/0.1% Tween, washed in PBS-Tween (0.1%), and
incubated overnight with the primary antibodies in PBS
containing 5% milk overnight at 4°C. Blots were washed
the next day in PBS-Tween and incubated two hours at
room temperature with horseradish peroxidase-conjugated
secondary antibody in PBS containing 5% milk. Blots
were washed with PBS-Tween and proteins were re-
vealed with chemiluminescence reagents (ECL Plus; GE
Healthcare Limited, Piscataway, NJ). Immunoprecipita-
tion of GFP (Green Fluorescent Protein) and GFP-YB-1
constructs were performed as described previously
[21]. Protein bands on western blots were quantified
using LI-COR Image Studio software 2.0 (LI-COR
Biosciences, Lincoln, NE). β-actin was used as a control
for protein loading. The background signal for each
band was determined using an identical area to the tar-
get band covering a region in the same lane where no
protein signal was observed. Results were determined
by calculating a ratio of target protein signal (minus
background) over β-actin signal (minus background).
Tsofack et al. BMC Cancer 2013, 13:303 Page 4 of 12
http://www.biomedcentral.com/1471-2407/13/303Immunofluorescence analysis
SK-OV-3 cells were plated on coverslips and transfected
the next day with control siRNA or siRNA sequences
against RPS4Xm RNA. Three days later cells were fixed
in 4% paraformaldehyde for 20 min at room temperature
(RT) and permeabilized with 0.15% Triton X-100 at RT
for 10 min. After washing with PBS, cells were blocked
with 3% BSA at room temperature for 30 min. After
blocking, the antibody against RPS4X was diluted in 1%
blocking buffer (1:100) and applied to the coverslips for
an overnight incubation at 4°C. The next day, coverslips
were washed with PBS and incubated with rhodamine-
secondary antibody (Santa Cruz) for 1 h30 min in the
dark at RT. After washing, coverslips were stained with
DAPI 10 min, washed, and mounted on glass slides. Slides
were viewed at 60X magnification (1.4NA oil-immersion
60X objective) and zoomed 2X for image acquisition on a
Nikon inverted diaphot confocal microscope equipped
with Krypton/Argon lasers (488 and 568 nm). Images were
captured with a BioRad MRC1024 confocal microscopy
system. Finally, images were analyzed (colored and merge)
using the Fiji-win32 software.
FACS and FITC-Annexin V analyses
Cells were transfected with either control siRNA or
siRNA against RPS4X. After 72 h, cells were fixed in 50%
ethanol overnight. Cells were then washed in phosphate-
buffered saline (PBS) and incubated for 30 min at 37°C in a
buffer containing propidium iodide and RNAses. Cells
were then analyzed on a Beckman-Coulter Epics Elite ESP
(Cambridge, MA, USA) flow activated cell sorter. Data
were analyzed with the MultiCycle software (Phoenix Flow
System, San Diego, CA, USA). To estimate apoptosis and/
or necrosis, we used the FITC Annexin V apoptosis detec-
tion kit I (BD Biosiences, Palo Alto, CA). Transfected cells
were treated 48 h with the indicated concentration of cis-
platin and then harvested to measure apoptosis/necrosis
following the manufacturer’s instructions.
Cisplatin treatment and sulforhodamine B colorimetric
assay
Cells were transfected with the indicated siRNAs and
allowed to grow for 24 hours. The next day, 10,000 cells
were seeded per well on a 96-well plate and incubated at
37°C for 24 hours. Different concentrations (0–40 μM) of
cisplatin were added to the cells in triplicate and cells were
then allowed to grow for an additional 48 hours. Cells were
fixed with tricholoroacetic acid (10% w/v) and stained
30 min with sulforhodamine B as described [22].
Statistical analysis
The Spearman correlation (two-tailed) and non-parametric
Wilcoxon-Mann–Whitney test were used to estimate the
correlation with clinicopathological variables and markersas continuous variables. Survival curves were calculated
according to Kaplan-Meier method coupled with a log-
rank test for survival analysis. Since survival times were
positively skewed, we took the median as the threshold
value for each marker (YB-1 and RPS4X). Univariable and
multivariable Cox proportional hazard models were used
to estimate the hazard ratio for each marker as continuous
variables. All statistical analyses were done using Statistical
Package for the Social Sciences software version 16.0
(SPSS, Inc.), and statistical significance was set at P < 0.05.
The R software version 2.10.1 (http://www.r-project.
org/) was used to estimate the growth rate, the IC50, and
the associated standard deviation. Briefly, the growth
curves were fitted to a mathematical model of the form
y = x0*(1 + r)
t, where x0 represents the 50,000 transfected
cells plated on day 0, r represents the growth rate, and
t represents the time unit (days). The dose response curves
were fitted to a standard exponential decay mathematical
model of the form y = y0 + A*e
kx where y0 represents the
minimal normalized intensity, A the intensity at time 0 and
k is the decay rate.
Results
RPS4X and YB-1 expression in ovarian cancer samples
It has been reported that YB-1 is overexpressed in ovarian
cancers [7,23]. Since we recently found an interaction be-
tween RPS4X and YB-1 proteins [15] that may affect clin-
ical outcomes of patients, we determined the levels of
expression of these proteins by immunohistochemistry in
192 clinical samples from women with ovarian cancer
(Table 1). (Note that for each immunohistochemistry stain-
ing experiments, samples of poor quality were excluded
from the statistical analyses). We correlated the expression
of these proteins with the mitotic index marker Ki67 from
the same samples. Figure 1 demonstrates examples of the
staining pattern obtained with the antibodies used against
YB-1, RPS4X, and Ki67. Expression of proteins in the epi-
thelium of the ovarian cancer tissues was observed and
scored according to the intensity of staining as low to
strong (1 to 5) (Figure 1). Both YB-1 and RPS4X were
mainly cytoplasmic, while Ki67 gave a nuclear staining.
The quality and validity of the antibodies against YB-1 and
Ki67 used in this immunohistochemistry study have been
described previously [18,19]. To confirm the validity of the
antibody against RPS4X, we performed western blot and
immunofluorescence tests on control and RPS4X-depleted
SK-OV-3 ovarian tumor cell lines. As indicated in
Figure 1D, the RPS4X antibody recognized a band of ap-
proximately 29 kDa that was depleted by two different
siRNAs specific to RPS4X mRNAs. The immunofluores-
cence signal was also reduced in a population of SK-OV-3
cells transfected with a siRNA against RPS4X compared to
siRNA control cells (Figure 1E). These results indicate that
the antibody is specific to the RPS4X protein.
Figure 1 Representative staining for immunohistochemistry
of YB-1, RPS4X, and Ki67 on a high-grade serous EOC TMA.
A, representative staining of each intensity by immunohistochemistry
for YB-1. From left to right: low to high intensity. B, representative
staining of each intensity by immunohistochemistry for RPS4X. From
left to right: low to high intensity. C, representative staining of each
intensity by immunohistochemistry for Ki67. From left to right: 0% of
total staining, 50% of total staining, and 100% of total staining.
D, western blot analysis of total protein extracts from SK-OV-3 cell
lines transfected with a siRNA sequence against RPS4X mRNA
(siRPS4X-A and siRPS4X-D) or transfected with a control (scrambled)
siRNA sequence. β-actin is used as a loading control. E, a representation
of immunofluorescence signals in SK-OV-3 cells transfected with a
siRNA sequence against RPS4X mRNA (siRPS4X-A) or transfected with
a control scrambled siRNA sequence (siCtrl). Nuclei are revealed by
DAPI staining (in blue).
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RPS4X and Ki67 expression in ovarian cancer. Over-
expression of YB-1 correlated significantly with totalexpression of Ki67 and expression of RPS4X in our clinical
samples (Table 2). As expected, the expression of RPS4X
correlated significantly with the expression of YB-1. It also
correlated positively with the expression of the mitotic
index marker Ki67.
We next investigated the correlation between clinico-
pathological features of ovarian cancer cases and the ex-
pression of YB-1 and RPS4X. We determined whether
the expression of YB-1 and RPS4X were associated with
survival time and disease recurrence in patients with
ovarian cancer using Kaplan-Meier plots. YB-1 was not
significantly associated with either survival or recurrence
time in our cohort (see Additional file 1: Figure S1). In
contrast, Kaplan-Meier plots for RPS4X showed that the
high expression of this biomarker is strongly associated
with an increased overall patient survival (P = 0.002)
(Figure 2A). Progression time was also significantly
shorter in patients with low RPS4X expression (P = 0.0004)
(Figure 2B). RPS4X also correlated significantly with
lower levels of residual disease (Table 2) and with a
lower disease stage (Table 2 and see Additional file 2:
Table S2). Finally, YB-1 and RPS4X expression levels
did not significantly correlate with patient age at diag-
nosis (Table 2).
In univariable Cox regression analysis, the level of
RPS4X protein was evaluated to reflect the relation be-
tween decreasing levels of RPS4X expression and ad-
verse prognosis. In this analysis, high expression of
RPS4X is associated with a high hazard risk (HR) for
survival (HR = 0.713; 95% Confidence Interval [CI] =
0.583-0.873, P = 0.001) (Table 3). It was also observed
that higher RPS4X expression was associated with a lon-
ger time to disease progression (HR = 0.761; 95%CI =
0.652-0.888, P = 0.001). In multivariable Cox regression
analysis, when standard prognostic variables were con-
sidered (age, stage and residual disease), RPS4X remained
an independent variable predicting a high risk of survival
(HR = 0.689; 95%CI = 0.545-0.871, P = 0.002) and a late
risk of progression in the multivariable model (HR =
0.751; 95%CI = 0.626-0.901, P = 0.002) (Table 3).
To summarize, all our statistical analyses indicate that
high expression of RPS4X is associated with less aggres-
sive ovarian tumors, slower disease progression, and
with less deaths associated with this disease.
Impact of RPS4X depletion on the growth of two serous
epithelial ovarian cancer cell lines
We examined the effect of depleting YB-1 protein on
RPS4X levels in the ovarian tumor line OVCAR-3. As
indicated in Figure 3, a depletion of YB-1 protein (by ap-
proximately two-fold) with two different siRNAs did not
have a significant effect on RPS4X protein levels (Figure 3A
and B). Two different siRNAs against our target proteins
were used in all experiments to avoid confounding results
Table 2 Spearman correlation test (two-tailed) for YB-1 and PRS4X expression (intensity) in EOC tissues and clinical
data of patients
YB-1 RPS4X Ki67 % total Stage Age Residual disease
YB-1 correlation 1 0.391** 0.315** −0.016 0.004 −0.053
Sig. (2-tailed) <0.001 <0.001 0.829 0.961 0.535
N 186 186 180 186 186 137
RPS4X correlation 0.391** 1 0.224** −0.180* 0.041 −0.193*
Sig. (2-tailed) <0.001 0.002 0.013 0.557 0.022
N 186 190 183 190 190 141
* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01 level (2-tailed).
Spearman correlation test were performed on clinical data, total Ki67%, YB-1, and PRS4X staining intensity observed in the intra-epithelial area of ovarian tumors.
Stage was evaluated according to the FIGO classification. “Sig.” in the table represents the P-value from Spearman correlation test. N is the number of cases
included in the statistical analysis.
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Similarly, a two-fold depletion of RPS4X protein did not
have a significant effect on YB-1 protein levels (Figure 3B).
These results suggest that RPS4X and YB-1 do not regulate
each other at the protein expression level in OVCAR-3
cells. The depletion of RPS4X in SK-OV-3 cells with the
siRPS4X-D sequence decreased YB-1 protein levels by 33%Figure 2 Kaplan-Meier survival for low and high intensity of
RPS4X in high grade serous EOC. A, Kaplan-Meier curves of
survival in our cohort. B, Kaplan-Meier curves of disease-free survival
in our cohort. N = number of patients. Significance (p) is indicated
by log-rank test. Subjects with low or high expression of RPS4X are
plotted (low = scores 1 to 3; high = scores 4 to 5 from Figure 1B).only (Figure 3C and D). In contrast, the siRPS4X-A se-
quence did not decrease YB-1 protein level significantly
(less than 14%) compared to the siControl transfection
based on the overlap of the error bars of the histogram in
Figure 3D.
We next investigated the effect of RPS4X depletion on
OVCAR-3 and SK-OV-3 cell growth. As indicated in
Figure 4, two different siRNAs against RPS4X (hereafter
designated siRPS4X-A and siRPS4X-D) significantly de-
creased the growth rate of OVCAR-3 and SK-OV-3 cells.
We further analyzed the cell cycle of transfected cells by
FACS analysis. As indicated in the summary histogram of
Figure 4E, siRPS4X OVCAR-3 transfected with siRPS4X
sequences showed an increase in S phase with a concomi-
tant decrease in the G1 phase of the cell cycle compared to
control siRNA transfected cells. Based on the growth rate
(Figure 4C), these results suggest that the siRPS4X stalls
OVCAR-3 cell proliferation in the S phase of the cell cycle.
SK-OV-3 transfected with siRPS4X sequences exhibited an
increase in the G2/M phase of the cell cycle with a con-
comitant decrease in the S phase. Based on the growth rate
(Figure 4D), these results suggest that siRPS4X stalls
SK-OV-3 cell proliferation in the G2/M phases of the
cell cycle. Examples of FACS analyses are shown in the
Additional file 3: Figure S2. The difference between
RPS4X-depleted OVCAR-3 and SK-OV-3 cell cycle be-
havior is currently unknown. Nevertheless, siRPS4X
decreased the proliferation rate in both cell lines.
To determine whether a depletion of RPS4X had an
impact on apoptosis, we analyzed siRPS4X transfected
cells with a FITC-Annexin V assay and compared them
to control siRNA transfected cells. A depletion of RPS4X
protein in OVCAR-3 cells did not increase the percent-
age of apoptotic or necrotic cells in culture (Figure 5). In
contrast, RPS4X depletion in SK-OV-3 cells increased
apoptosis by 17% (Figure 5). These results indicate that
the SK-OV-3 cells are more sensitive to the depletion of
RPS4X protein than the OVCAR-3 cells.
Table 3 Cox regression analyses representing the statistical association between RPS4X expression and outcome in
patients with high-grade serous ovarian cancer patients
Univariable analysis Multivariable analysis
HR (95%CI) P HR (95%CI) P
Survival age 0.998 (0.977 1.019) 0.841 0.999 (0.974 1.025) 0.952
stage 1.713 (1.179 2.490) 0.005 1.432 (0.804 2.552) 0.223
Res. Dis. 1.926 (1.490 2.491) 0.000 1.732 (1.309 2.290) 0.000
RPS4X 0.713 (0.583 0.873) 0.001 0.689 (0.545 0.871) 0.002
Progression age 0.993 (0.976 1.009) 0.381 0.984 (0.965 1.004) 0.110
stage 2.238 (1.684 2.973) 0.000 1.877 (1.257 2.805) 0.002
Res. Dis. 1.714 (1.425 2.060) 0.000 1.552 (1.262 1.908) 0.000
RPS4X 0.761 (0.652 0.888) 0.001 0.751 (0.626 0.901) 0.002
Res. Dis. = amount of residual disease at time of primary resection of ovarian tumor. Age = age of patient at the diagnosis. HR = hazard ratio. CI = confidence
interval. P = p value.
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cisplatin resistance
We first compared the expression of endogenous RPS4X
in untransfected OVCAR-3 and SK-OV-3. As shown in
Figure 6A and B, RPS4X protein levels were 1.5-fold
higher in OVCAR-3 cells than SK-OV-3 cells. Although
such cells were derived from patients with malignant as-
cites resistant to clinically relevant concentrations of cis-
platin (www.atcc.org), we examined whether a depletion
of RPS4X could increase cisplatin resistance further. As in-
dicated in Figure 6C and D, RPS4X-depleted ovarian can-
cer cells were more resistant to cisplatin than control
siRNA transfected cells. The calculated IC50 in OVCAR-3
cells for the control siRNA, siRPS4X-A, and siRPS4X-DFigure 3 Western blot analysis of total protein extracts from OVCAR-
sequences. A, OVCAR-3 cells were transfected with the indicated siRNA m
on SDS/PAGE gel, and membranes were hybridized with anti-YB-1, anti-RPS
presenting the ratio of YB-1 or RPS4X signal over β-actin signal from the w
indicated siRNA molecule and 48 hours later total protein extracts were pu
anti-YB-1, anti-RPS4X, and anti-β-actin. Representative blots are presented. D
signal from the western blots in panel C. All experiments were performedwere 0.9, 2.7, and 1.8 μM, respectively (Unpaired stu-
dent t-test: P = 0.0084 for siRPS4X-A vs siCTRL and
P = 0.025 for siRPS4X-D vs siCTRL) (Figure 6E). The
calculated IC50 in SK-OV-3 cells for the control siRNA,
siRPS4X-A, and siRPS4X-D were 9.1, 25.1, and 36.3 μM,
respectively (Unpaired student t-test: P = 0.00066 for
siRPS4X-A vs siCTRL and P = 0.0001 for siRPS4X-D vs
siCTRL) (Figure 6F). These results indicate that cells that
express low levels of RPS4X are more resistant to cis-
platin and a depletion of RPS4X causes further cisplatin
resistance in both serous epithelial ovarian cancer cell
lines tested in this study.
We next analyzed the impact of cisplatin on cell death in
transfected cells with a FITC-Annexin V assay. OVCAR-33 and SK-OV-3 cell lines transfected with different siRNA
olecule and 48 hours later total protein extracts were purified, loaded
4X, and anti-β-actin. Representative blots are presented. B, Histograms
estern blots in panel A. C, SK-OV-3 cells were transfected with the
rified, loaded on SDS/PAGE gel, and membranes were hybridized with
, Histograms presenting the ratio of YB-1 or RPS4X signal over β-actin
in duplicate.
Figure 4 Cell growth in RPS4X-depleted OVCAR-3 and SK-OV-3 cells. A, cell growth of OVCAR-3 cells transfected with siCtrl, siRPS4X-A and
siRPS4X-D molecules. Cells were transfected with the indicated siRNA sequences. The next day 10,000 cells were seeded in 60-mm plates and
appropriate plates were counted every other day using a hemacytometer. B, Cell growth of SK-OV-3 cells transfected with siCtrl, siRPS4X-A and
siRPS4X-D molecules. Cells were transfected with the indicated siRNA sequences. The next day 50,000 cells were seeded in 60-mm plates and
appropriate plates counted every other day using a hemacytometer. C, Histogram representing the growth rate of OVCAR-3 transfected cells
(from at least three transfections for each siRNA sequence) calculated from the growth curves in A. Error bars represent the standard deviation.
(Unpaired student t-test: P = 7.6 × 10-5 for siRPS4X-A vs siCTRL and P =2.4 × 10-6 for siRPS4X-D vs siCTRL). D, Histogram representing the growth
rate of SK-OV-3 transfected cells (from at least three transfections for each siRNA sequences) calculated from the growth curves in B. Error bars
represent the standard deviation (Unpaired student t-test: P = 3.9 × 10-7 for siRPS4X-A vs siCTRL and P = 8.7 × 10-6 for siRPS4X-D vs siCTRL). Growth
rates were estimated as described in materials and methods. E, Percentage of OVCAR-3 and SK-OV-3 transfected cells in each phase of the cell
cycle. Cells were transfected with the indicated constructs in duplicates and subjected to FACS analysis 72 h later. (The siRPS4X represent data
from cells transfected with siRPS4X-A and siRPS4X-D performed in duplicata). Data are the mean ± SE.
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crease in apoptosis when treated 48 hours with 2 μM cis-
platin (Figure 5). There was no significant increase in
necrosis. In contrast, RPS4X-depleted OVCAR-3 cells did
not exhibit an increase in apoptosis or necrosis after
48 hours of cisplatin treatment. Similarly, SK-OV-3 cells
transfected with a control siRNA showed a 30% and 2% in-
crease in apoptosis and necrosis respectively when treated
for 48 hours with 15 μM cisplatin (Figure 5). In contrast,RPS4X-depleted SK-OV-3 cells showed only a 7% increase
in apoptosis after 48 hours of cisplatin treatment (Figure 5).
There was no increase in necrosis. Altogether these results
indicate that RPS4X-depleted ovarian cancer cells are re-
sistant to apoptosis induced by cisplatin.
RPS4X interacts with YB-1 in ovarian cancer cells
We previously showed that RPS4X interacts with a
tagged YB-1 in a breast cancer cell line [15]. To confirm
Figure 5 (See legend on next page.)
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Figure 5 Apoptotic and necrotic events in RPS4X-depleted cells were assessed in the presence of cisplatin by flow cytometry with
Annexin V/PI staining. Cells were transfected with the indicated siRNA sequences (siControl and siRPS4X-A) and 48 hours later cells were
treated for 48 hours with the indicated concentration of cisplatin. In each graph, the P1 section (top left) represents necrotic cells, the P2 section
(top right) represents both apoptotic and necrotic cells, the P3 section (bottom left) represents healthy cells, and the P4 section (bottom right)
represents apoptotic cells. The number and percentage of cells in each section are indicated below each graph.
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and a control GFP expression vectors were transfected into
SK-OV-3 cells. The next day the GFP-YB-1 construct was
precipitated with an antibody against the GFP tag
and the presence of RPS4X in the immunoprecipitate
was detected by immunoblotting (see Additional file 4:
Figure S3). Endogenous RPS4X was only found in theFigure 6 RPS4X depletion increases cipslatin resistance in OVCAR-3 an
expression of RPS4X in untransfected OVCAR-3 and SK-OV-3 cells. β-actin is
signal over β-actin signal from western blots. Experiments were performed
cells. D, Cisplatin dose response curves for transfected SK-OV-3 cells. Cells w
response curves were determined by the sulforhodamine B colorimetric ass
(from at least three transfections for each siRNA sequences) calculated from
deviation. (Unpaired student t-test: P = 0.0084 for siRPS4X-A vs siCTRL and P
SK-OV-3 transfected cells (from at least three transfections for each siRNA se
represent the standard deviation. (Unpaired student t-test: P = 0.00066 for si
estimated as described in materials and methods.GFP-YB-1 immunoprecipitate indicating an interaction be-
tween RPS4X and YB-1 in ovarian cancer cells as well.
Discussion
The expression of YB-1 in ovarian carcinomas has been
correlated with a poor prognosis in several studies in-
cluding one focused on serous ovarian cancer [7,23]. Ind SK-OV-3 cells. A, One example of a western blot showing
used as a loading control. B, Histogram presenting the ratio of RPS4X
in duplicate. C, Cisplatin dose response curves for transfected OVCAR-3
ere transfected with the indicated siRNA molecules. Cisplatin dose
ay. E, Histogram representing the IC50 of OVCAR-3 transfected cells
the drug response curves in A. Error bars represent the standard
= 0.025 for siRPS4X-D vs siCTRL). F, Histogram representing the IC50 of
quences) calculated from the drug response curves in B. Error bars
RPS4X-A vs siCTRL and P = 0.0001 for siRPS4X-D vs siCTRL). IC50 were
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lationship between ovarian cancer patient survival and
YB-1 expression [24]. Such contrasting results may be
due to the small numbers of ovarian tumor samples,
specifically of the serous type (less than 40 samples of
both low and high grades), that were used in past studies
[7,23,24]. Another confounding parameter in the inter-
pretation of the results is the anti-YB-1 antibodies used
in the different studies. Antibodies recognizing epitopes
on the C-terminus [7,24] or the N-terminus portion of
the YB-1 protein (our study) as well as the immunohis-
tochemistry protocol can impact staining [25]. Finally, as
our study focused exclusively on high-grade serous epi-
thelial ovarian cancers, it is possible that within this sub-
set of serous cancer YB-1 has little prognostic value. In
contrast, the level of RPS4X may be a better prognostic
biomarker than YB-1 in serous epithelial ovarian cancers.
Our recent analyses on YB-1 in breast cancer cell lines
resistant to cisplatin have indicated an interaction be-
tween RPS4X and YB-1 [15]. As platinum-based regimen
is a major treatment for ovarian cancer, we sought to de-
termine whether the expression of RPS4X could have
prognostic significance in this cancer type. In this study,
we showed by immunohistochemistry that high expression
of RPS4X correlated with overall survival and disease free
progression. Low expression of RPS4X correlated signifi-
cantly with tumor stage. These results suggest that RPS4X
is a potential prognostic marker for high-grade serous epi-
thelial ovarian cancer at the protein level. To our know-
ledge, there is no published study on RPS4X levels in
ovarian cancers. RPS4X will need to be validated in an in-
dependent cohort of patients to confirm its clinical utility.
In addition, a more quantitative way of measuring RPS4X
expression, as for example real-time quantitative RT-PCR,
could be envisioned.
An important aspect of RPS4X protein expression is
its association with cisplatin resistance in different cell
lines. The SK-OV-3 cell line is more resistant to cisplatin
than the OVCAR-3 cell line [26,27]. Interestingly, the
expression of endogenous RPS4X protein is lower in the
more cisplatin resistant SK-OV-3 cell line than the
OVCAR-3 cell line. In addition, a depletion of RPS4X in
both the OVCAR-3 and SK-OV-3 ovarian cancer cell
lines induced cisplatin resistance and is consistant with
our previous data on RPS4X depleted breast cancer cell
lines resistant to cisplatin [15]. Such results suggest that
RPS4X would also have predictive values with regards to
platinum-based chemotherapy. A major challenge with
platinum-based regimen is that ovarian cancers can be
either intrinsically resistant to treatments or will become
resistant during therapy [5]. As the immunohistochemis-
try study was performed on serous high-grade ovarian
tumors from patients who had not received chemothera-
peutic treatment, the patients showing low expression ofRPS4X in their tumor tissues at surgery could correlate
with an intrinsic resistance to platinum-based drugs.
More precisely, cancer cells with low expression of
RPS4X present in high-grade tumors that have never
been in contact with platinum would correspond to cells
exhibiting a pre-existing mechanism for resistance to
such a drug. The exact mechanism by which a depletion
of RPS4X confers cisplatin resistance is not known. One
hypothesis is that depletion of RPS4X could induce a
ribosomal stress which in turn leads to a slower growth
rate as observed in siRPS4X transfected ovarian cancer
cell lines. It has been suggested that a reduced growth
rate could constitute a significant event in the survival
of cancer cells following a major stress like cisplatin
treatment [28,29]. Finally, differential translation of not
only several survival factors in addition to proteins crit-
ical in the control of apoptosis during cisplatin response
may be affected as well in RPS4X-depleted cells. Large-
scale proteomic analyses may help identifying such crit-
ical regulators in RPS4X-depleted cisplatin resistant cells.
In addition, a thorough analysis of the impact of RPS4X
levels on different types of reagents used in chemother-
apy is also required.
Conclusions
To conclude, we have established that RPS4X is a new
promising prognostic marker for patients with high-
grade serous ovarian cancer. More importantly, if RPS4X
is shown to be predictive of cisplatin response either
alone or in combination with other markers, this could
be useful when selecting first line therapies for patients
with serous ovarian cancer.
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intensity of YB in high grade serous EOC.
Additional file 2: Table S1. Wilcoxon-Mann–Whitney test for PRS4X
expression (intensity) in EOC tissues and stage and residual disease of
patients.
Additional file 3: Figure S2. Examples of FACS analyses with the
indicated cell lines and siRNA sequences.
Additional file 4: Figure S3. Co-imunoprecipitation of endogenous
RPS4X protein with GFP-YB-1 in transfected SK-OV-3 cells. Cells were
transfected with GFP or GFP-YB-1 expression vectors and the next day
GFP or GFP-YB-1 proteins were immunoprecipitated with an anti-GFP
antibody. Endogenous RPS4X is co-immunoprecipitated only in cells
transfected with the GFP-YB-1 construct. WCE = whole cell extract; anti-
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corresponding to GFP-YB-1 and the endogenous YB-1 proteins are
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